Some inhibitors of the Wnt/β-catenin pathway, such as salinomycin, celecoxib, and Wnt-C59, restore TMZ sensitivity in resistant GBM cells by reducing MGMT expression in GSCs. Here, MGMT is linked to glioblastoma.